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Abstract
Background: When invited for the first time at age 50, most women in Germany have to decide whether they wish
to participate in the German mammography screening programme. For ethical reasons, screening decisions should
be informed choices, but this is rarely the case with mammography screening. Decision aids are interventions with
the potential to support informed choice by improving the following factors: knowledge, clarity of personal attitude,
and implementation of an intention. Currently, no systematically evaluated decision aid exists for the German
mammography screening programme. Therefore, the objective of this randomized controlled trial is to assess the
effectiveness of a decision aid for first-time mammography screening programme invitees.
Methods/Design: We have developed a decision aid for women invited to the mammography screening
programme for the first time based on the criteria of the International Patient Decision Aids Standards Collaboration.
The effectiveness of the decision aid will be evaluated in a randomized controlled trial with a 3-month follow-up. We
will invite 7400 women aged 50 years from the district of Westfalen-Lippe, Germany, to participate. This sample will be
drawn from registration office data. The primary outcome will be informed choice. The secondary outcomes will be
the components of informed choice (knowledge, attitude, decision/implementation). Decisional conflict, decision
regret, eHealth literacy, health behaviours, perceived behavioural control, subjective norms, invitation status, and
demographic variables will be assessed. Data will be collected online at baseline, post-intervention, and at the
3-month follow-up. Participants will be randomized to receive either the decision aid or usual care (invitation and
standard leaflet of the mammography screening programme).
Discussion: This paper describes the evaluation of a decision aid for the German mammography screening
programme in a randomized controlled trial. If the decision aid proves to be an effective tool to enhance the rate of
informed choice, it will be made accessible to the public and the use of this decision aid for first-time invitees will be
recommended. The long-term effect could be an improvement in informed choices in women invited to the
mammography screening programme.
Trial registration: German Clinical Trials Register DRKS00005176.
Keywords: Mammography screening, Informed choice, Decision aid, Randomized controlled trial
Background
Informed choice has become an important public health
issue [1]. In the face of growing discussion about the
usefulness of mammography screening [2], there is an
increased need to involve women in the screening deci-
sion. For ethical reasons, their choices should be informed
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[3]. Despite a lack of evidence for the all-cause mortal-
ity benefit of mammography screening [4], all women
in Germany between the ages of 50 and 69 are invited
every 2 years to the mammography screening programme
(MSP). The invitation comes with a pre-specified appoint-
ment. However, each recipient can choose whether she
wishes to participate. This decision is made in the context
of scientific uncertainty [5] about the extent of benefits
and harms of mammography screening. Nevertheless, the
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accompanying information provided by the inviting orga-
nization makes it appear that choosing to attend is a more
appropriate decision, thus removing uncertainty from the
message. Research shows that an informed choice is not
achieved in a large proportion of mammography screen-
ing decisions: Mathieu et al. arrived at the figure of 48%
informed choices [6]; van Agt et al. found 88% [7]. Indeed,
the term “uninformed compliance” [8] has been coined
to describe participation in this screening. Uninformed
compliance is a major public health problem in the Ger-
man MSP, since many women in the target group of the
MSP have unrealistic expectations regarding its potential
benefits [9]. Weighing benefits against harms is a value
judgment, thus no correct answer can be determined [10]
making this decision preference sensitive.
To identify solutions towards increasing the proportion
of women making informed choices, the dimensions of
this construct must be specified. A decision is classified
as informed if the decision maker has good knowledge
of the situation as well as an attitude congruent with the
choice, and then implements the decision [11]. Therefore,
to enable an informed choice, women invited to the MSP
need to be informed about the existence and probability of
positive and negative outcomes and given the opportunity
to clarify the meanings of those outcomes for them per-
sonally. If these two conditions are met, implementation
of a decision is also more likely.
The question then is how to meet these conditions.
One innovative approach to addressing the issue of unin-
formed compliance is the use of decision aids (DAs). It is
in preference sensitive decisions that a DA is most useful
though the level of detail that should be used in DAs is
controversial [12].
There is ongoing discussion about how useful quanti-
tative information in DAs is for the deciding person [13].
From an informed choice perspective, not only the exis-
tence of a benefit or harm but also its probability is impor-
tant for the decision [14]. Otherwise it is not possible to
weigh the different outcomes against each other.
To assess concordance in decision making, several
options exist. Sepucha and Fowler [15] recommend a sim-
ple match using decision (in form of a single preference
question) and implementation; this leaves out attitude
(which would require several questions on the different
outcomes of an option).While preference already includes
a decisional element, attitude is more distal targeting
the different outcomes an option has. In this study, we
therefore use attitude and knowledge scores to determine
decision quality.
DAs are tools that help individuals choose between “two
or more medically-appropriate healthcare options” [16]
(p. 2). Research has shown that DAs are a promising
strategy to increase the rate of informed choices in mam-
mography screening [6]. To date, however, few studies
have examined the effect of DAs on informed choice in
such screening.
For the established MSP in Germany, there are no sys-
tematically evaluated DAs. To our knowledge, the only
DA that exists was evaluated with a convenience sample
of n=152 in a cross-sectional study design [17]. It does
not meet International Patient Decision Aids Standards
(IPDAS) to a high degree. Common shortcomings of stud-
ies in other mammography screening contexts are that
they analyse only the immediate effects of DAs and do not
follow up on the long-term effects on knowledge and deci-
sional conflict [18]. Additionally, they do not target the
age group for which mammography screening is intended
[6, 19] or assess only high-risk populations [20, 21]. There-
fore, it is unclear whether a DA would be beneficial for
the GermanMSP or what long-term effects it would have.
To meet this lack of a suitable DA, we developed a DA for
first-time MSP invitees.
The present study aims to assess the effect of an inter-
active online DA on informed choice in a randomized
controlled trial using a representative sample. The pri-
mary objective is to evaluate whether the DA results in
more women making an informed choice. The secondary
objectives are to evaluate whether the DA (1) improves
knowledge of the MSP, (2) clarifies attitudes on the MSP,
(3) changes intentions to participate in the MSP, (4) is
affected by background factors (e.g. education level) in
its influence on the primary and secondary outcomes, (5)
lowers decisional conflicts, and (6) differs in its long-term
effects depending on the outcome group of the screening
(true positive, false positive, negative).
Methods/Design
Design
This study is a non-blinded two-arm randomized con-
trolled trial, since it was obvious to the participants
whether they received just questionnaires or also an
online decision aid. The participating women will be ran-
domized to either (1) the DA (intervention group) or
(2) usual care (control group). The random allocation
will be on a 1:1 ratio basis. This study will be con-
ducted in Wesfalen-Lippe, Germany. The usual care for
women aged 50 in Germany involves an invitation from
theMSP accompanied by an information leaflet (see [22]).
Therefore, both study groups will receive these standard
materials. The online assessments will be conducted at
baseline (T1), at post-intervention (T2), and at a 3-month
follow-up (T3) (Fig. 1).
Ethical approval
Ethical approval was obtained from the Ethics Commis-
sion of the Medical Association Westfalen-Lippe and the
Medical Faculty of the University of Münster. Data han-
dling will conform to the data protection legislation of
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Fig. 1 Trial flow diagram
the federal state of North Rhine-Westphalia. We have
also obtained approval from the data protection officer at
Bielefeld University.
This research project is independent of theMSP. Invited
women will be informed about the content, purpose, and
procedure of the study, and we will obtain their written
informed consent before proceeding. Personal data will
be stored separately from research data. The first, second,
and third assessments (T1, T2, and T3) can be linked to
each other by means of a self-generated code consisting of
the following elements: day of the month the mother was
born, first letter of the first name of the mother, day of the
month the father was born, first letter of the first name of
the father, and first letter of own place of birth. This way
the questionnaires cannot be associated with any personal
data. All personal data will be deleted after completion of
the study. Participation in the study will be voluntary and
the participants may revoke consent at any time.
Participants’ eligibility
Women aged 50 will be eligible for this study because they
are invited to theMSP for the first time.Women who have
ever been diagnosed with breast cancer will be excluded
since they are not targeted by the MSP. Previous mam-
mograms for diagnostic or screening purposes will not
influence eligibility.
Recruitment
The sample will be representative of the above-described
study population in the district of Westfalen-Lippe. The
data will stem from the registration offices of this district,
which have consented to their data being used in this
study. The sample will consist of women with birth
months of March to May 1964. We will make the follow-
ing random selection from our data pool: 2000 women
with the birth month of March, 2000 women with the
birth month of April, and 3400 women with the birth
month of May. The sampling will take place (draw-
ing without replacement) after the sampling of another
study—Informed Choice of German and Turkish Women
for Participation in the MSP (InEMa) [23]. All women
with a positive name algorithm for a Turkish migration
background have been assigned to the InEMa study (see
[24] for information on the name algorithm). Therefore,
the sample for the present study will be drawn from a
data pool without positive name algorithms. Accordingly,
no women with a Turkish migration background will be
present in our sample, and this factor will be considered
in the analysis and interpretation of the results.
Decision aid
The DA was developed and piloted as part of this study.
The DA and questionnaires for evaluation were pro-
grammed in Unipark, an online survey tool (QuestBack
GmbH, Cologne, Germany). The structure of the DA was
based on that of Mathieu et al. [19]. The DA was concep-
tualized as an interactive online tool consisting of a static
information part and an interactive part.
We conducted a pilot study in March 2014, which
showed that our study methods were feasible and accept-
able to women aged 50. This quantitative pilot, to
which 300 women were invited of which 53 participated,
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also showed that women accessed the DA and worked
through it and that the questionnaires were accessed
and answered. The pilot indicated that about a third of
women dropped-out of the study prematurely. In a pre-
ceding qualitative pre-test both DA and questionnaires
were evaluated with women of the target group through
think-aloud protocols. The DA was additionally qualita-
tively piloted with experts from the National Network
Women and Health.
In line with IPDAS criteria [25], the DA presents the
options of choice (participation or non-participation in
the MSP) in a decision-relevant context. The advantages
and disadvantages of the MSP and their probabilities are
described. These include the probabilities of a positive
and negative screening result in absolute numbers sup-
ported by graphic presentations to allow women to form
a realistic expectation regarding the initial outcome of
the screening. We explain overdiagnosis, overtreatment,
and the procedure following a positive result. Positive
and negative information are presented in a balanced way
according to current evidence. Step-by-step navigation
through the websites of the interactive online DA facili-
tates a structured progress. Participants receive tailored
feedback based on previous entries directly before making
the decision. The studies from which the data for the DA
originate are cited and provide the participants with easy
access to the original sources via links.
A structured decision-making process in several steps
is at the core of the DA. Participants have the opportu-
nity to express personal values that are relevant for the
decision and to clarify these for themselves. Participants
have the option of printing their personal results and the
static information section at the end [see Additional file 1]
and to discuss matters with others. There is also an input
window for remaining questions at the end of the DA.
Information part
The information part of the DA contains the standard
information that women receive together with the invita-
tion to the MSP [22]. The DA specifies all event proba-
bilities based on the same population of 200 women over
20 years. In the presentation of outcome probabilities, the
information part goes beyond the standard information.
All probabilities are additionally represented as crowd-
figure pictograms [see Additional file 1], thereby simul-
taneously indicating the positive and negative frames of
outcomes. This type of pictorial information is benefi-
cial [26]. Additionally, the probability of dying from breast
cancer is presented in relation to the likelihood of all-
cause mortality. Uncertainty in the evidence is described.
Interactive part
The interactive part consists of three steps. In the
first step, the women assign the information items to
the following categories: (1) in favour of mammogra-
phy screening; (2) neither for nor against such screen-
ing; and (3) against the screening. In the second step,
the women rate each point according to its importance
in the decision. In the third step, the women make a
decision. Through this approach, the importance of a
personal value-based assessment of information is high-
lighted. An additional PDF file shows this in greater detail
[see Additional file 1].
Consent and data collection
The letter of invitation to the study, detailed study infor-
mation, a consent form, and a return envelope will be sent
by post 3 weeks in advance of the estimated date of receipt
of the invitation to the MSP. The consent form will also
provide for the possibility of specifying that the recipient
does not have access to an email address. To increase the
response rate, 1 week after the written invitation to partic-
ipate in the study, a reminder and thank-you postcard will
be mailed out.
Three weeks after the invitation is sent out, all women
who gave informed consent and provided us with an email
address will be emailed the link to the baseline ques-
tionnaire (T1). Women whose consent form is received
3-5 weeks after the invitation will receive the link at 5
weeks after the invitation. Women whose consent form is
received later than 5 weeks after the invitation will receive
the link at 7 weeks.
The link to the second assessment (T2) will be sent to
participants 2 weeks after the first email. Women will be
randomly assigned to the intervention or control group,
and accordingly, receive a link either to the DA and sec-
ond assessment or only to the second assessment. The link
to the third assessment (T3) will be sent to the women
3 months after T2 when the screening appointment is
assumed to have passed. A reminder and thank you will be
emailed to all women who initially agreed to participate
10 days after sending the survey link at T1, T2, and T3.
Primary outcomemeasure
The questionnaire was developed as part of another
project (InEMa) and adapted for online use as well as for
the evaluation of an intervention. For an overview of study
outcome measures, see Table 1.
Informed choice will be measured according to the
three-dimensional classification framework of Marteau
et al. [11], which covers knowledge, attitude, and imple-
mentation. The individual dimensions function addition-
ally as secondary outcomes and are described below.
Secondary outcomemeasures
Intention to participate in theMSP will be measured using
one item regarding intention to participate in the next 3
months (yes/no/undecided).
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Table 1 Outcome measures
Measures T1 T2 T3
Intention to participate in the MSP X X
Uptake of the MSP X
Attitude X X X
Knowledge X X X
Perceived behavioural control X X
Subjective norms X X
Decisional conflict X X X
Decision regret X
Result of the MSP X
Result and acceptability of the DA X
Invitation status X
Decision stage X




Uptake of the MSP will be measured using one
item regarding participation in the last 3 months
(MSP/opportunistic screening/none).
Attitudewill bemeasured using four items adapted from
Marteau et al. [11] and according to the reasoned action
approach of Fishbein and Ajzen [27]. Three semantic dif-
ferentials (important/unimportant; a good thing/a bad
thing; beneficial/harmful) will assess instrumental atti-
tude. One semantic differential will assesses experiential
attitude (pleasant/unpleasant). Items will be rated on a
five-point scale.
Knowledgewill be measured using sevenmultiple choice
items, with two to four answer options. The questions
will cover the following: (1) screening for people with-
out symptoms; (2) frequency of positive screening results;
(3) meaning of a positive result; (4) potential to detect
every cancer; (5) more diagnoses with the MSP; (6) more
breast cancer deaths without the MSP; and (7) overdiag-
nosis and overtreatment. For each item, “do not know”
will be offered as an option. Most questions will ask
for nun-numeric information. Only Question 2 will ask
for numeric information through four ranges of values
covering the base population used in the question. This
information is considered to be important as all women
participating in the MSP will receive a result and a real-
istic expectation on the probability of both positive and
negative results is important.
Perceived behavioural control will be measured using
two items developed following the reasoned action
approach of Fishbein and Ajzen [27] and rated on a five-
point scale (“Whether I participate in the MSP is up to
me”; “If I wanted to, I could participate in the MSP”).
Additionally, 15 items (four items at T2 and T3) mea-
suring control beliefs will be rated on a five-point scale
with the anchors of “agree” and “disagree”. The items
will assess logistic barriers (e.g. not having time for the
appointment), trust in the MSP, and fear of pain.
Subjective norms will be measured using two items
developed according to the reasoned action approach of
Fishbein and Ajzen [27] and rated on a five-point scale
(“Most people who are important to me think that I
should/should not participate in the MSP”; “Most people
like me would/would not participate in the MSP”). Addi-
tionally, five items will measure normative beliefs rated
on a five-point scale, ranging from “advise” to “disadvise”
with the additional option of “no advice”. These items
will assess the direction of advice of doctors, family, and
friends.
Decisional conflict will be measured using the SURE
(Sure of myself; Understand information; Risk-benefit
ratio; Encouragement) test [28]. This four-item test with
the answer options yes and no will assesses knowledge
of options, clarity of importance of advantages and dis-
advantages, sufficient level of support, and being sure
about the best choice. Since no German translation of
this scale is available, the scale was translated as part of
this study, and indices of reliability and validity will be
published.
Decision regret will be measured using the Decision
Regret Scale [29]. The five items will be rated on a
five-point scale (“strongly agree” to “strongly disagree”).
Since no German translation of this scale is available, the
scale was translated as part of this study, and indices of
reliability and validity will be published.
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Result of the MSP will be assessed using two items
regarding the result of the MSP and the result of further
diagnostics. The answers will allow grouping into four cat-
egories: (1) negative result; (2) false-positive result; (3)
true-positive result, and (4) positive result with further
diagnostics pending.
Result and acceptability of the DA will be measured
using one item assessing whether the tailored graphic in
the DA was balanced, and four items will assess accept-
ability of the DA regarding length, amount of infor-
mation (too much/too little/just right), one-sidedness
(pro/balanced/against), and helpfulness in decision mak-
ing (yes/neither/no).
Invitation status will be measured using two items
assessing whether an invitation was received and whether
the appointment specified in the invitation had already
passed.
Decision stage will be measured using one item follow-
ing IPDAS criteria with the answer options being “not
thought about it”, “contemplating it”, “close to deciding”,
and “choice already made”.
Use of/experience with other screeningswill be measured
using items on (1) the use of other screenings and (2) ever
having received a false-positive screening result (including
false-positive mammogram).
eHealth literacy will be measured using the eHealth Lit-
eracy Scale [30]. Its German translation has recently been
validated [31].
Internet use will be measured using two items regarding
time spent seeking information online and importance of
the Internet for health information.
Demographics will be measured using items assessing
education level, main language, health insurance, partici-
pation in a health insurance bonus programme, and breast
cancer in a first-degree female relative.
Sample size
Sample size was calculated using G* Power for the pri-
mary outcome (informed choice). Based on the study of
Mathieu et al. [19], we determined a difference in the
proportion of informed choices of 7 percentage points
as the minimum clinically important difference for the
power calculation. A sample size of 740 women (370 per
arm based on a 1:1 allocation ratio) will enable the detec-
tion of a between-group difference of 7 percentage points
given 80% power and a 5% (one-tailed) significance level.
Allowing for an estimated response rate of 15% and early
drop-out of one-third of initial participants, we aim to
invite 7400 women to take part in the study.
Data analysis
The data will be exported from Unipark and analysed
with SPSS version 21.0 (IBM Corp., Armonk, NY) and
Mplus version 7.0 (Muthén & Muthén, Los Angeles, CA).
Data cleaning and analyses will be performed using SPSS
and Mplus syntax operations. We will conduct descrip-
tive analyses to describe the study population. Possible
baseline differences between trial arms will be statistically
tested. We will adjust further analyses for imbalances in
the baseline scores.
The primary analysis will be by intention to treat. As
sensitivity analyses, only completers of all assessments
will be analysed. The impact of the DA on the primary
outcome will be analysed using χ2-tests. The numeric
secondary outcomes will be analysed using analyses of
variance; categorical secondary outcomes will be analysed
using χ2-tests. Additionally, latent change model analyses
will be performed for continuous longitudinal outcome
data. Latent transition analyses will be performed for cat-
egorical longitudinal outcome data. To handle missing
data, full informationmaximum likelihood estimation will
be conducted in MPlus. To investigate the mediation and
moderation effects of the secondary and demographic
variables, mediation and moderation analyses will be per-
formed using the PROCESS macro version 2.13 (Andrew
F. Hayes, http://www.processmacro.org). in SPSS. As part
of the questionnaire adaptation, factor, reliability, and
correlation analyses will be performed.
Discussion
This study will investigate the effects of a DA on informed
choice in mammography screening. Studies on DAs in
mammography screening are scarce. The DA developed
for this study will consist of a static information part
and an interactive part. No negative impact on the study
participants is expected since the DA will include infor-
mation that women ordinarily receive through usual care
regardless of participation in this trial.
One strength of this study is its robust design and
follow-up assessment at 3 months. This will allow eval-
uation of the long-term effects of the DA. Furthermore,
in contrast to most randomized controlled trials, we will
focus not only on the effectiveness of the DA, but also on
mediating variables, thereby offering a model to explain
the effect on informed choice.
There are also several challenges with this study. Espe-
cially, enrolling a sufficiently large sample is a major diffi-
culty, which we hope to overcome by using reminders and
underscoring the importance of this study and the future
merits for women confronted with the MSP.
One potential disruptive influence on the study results
will be previous screening experiences of participants.
Therefore, only women aged 50 who are invited for the
first time to the MSP will be included in the study. In
addition, we will ask for information about previous expe-
riences with breast cancer screening.
One potential problem with the online survey of a pop-
ulation sample is a low, selective participation rate. In
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the statistical analyses, we will adjust for interference by
applying multivariate methods. No women with a Turkish
migration background will be present in our sample, and
this will have to be considered in the analysis.
In summary, this will be the first study to assess the
impact of an online DA for the GermanMSP in a random-
ized controlled trial. The results of this research will be
important for the following reasons: (1) they will provide
information on the level of informed choice under usual
care; (2) they will show whether a DA is helpful in increas-
ing informed choice; and (3) they will indicate whether
a DA is acceptable to women. The DA developed in this
project will provide a support tool for decision making
that can be used in further studies on informed choice
and evaluated in other populations. If the DA proves
to be effective in increasing the proportion of informed
deciders, our results will be relevant to practice. Hence,
the DA could be used on a large scale.
Additional file
Additional file 1: Sample personal decision aid PDF. This PDF can be
downloaded at the end of the online DA. It includes the static information
part as well as the responses that were previously given by the user.
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